AzTrials
AzTrials

Ventriculitis, CerebralEVD-InfectNCT04736407

Diagnostics of External Ventricular Drain Infections in Neurosurgical Patients

An observational study of Ventriculitis, Cerebral, run by Karolinska University Hospital at 1 site in Sweden.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

External ventricular drains (EVD) are small tubes used in neuro-critical care inserted to measure pressure and treat acute build-up of fluid in the brain by draining the cerebrospinal fluid (CSF) in the ventricles, often following an event of traumatic or spontaneous bleeding. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Ventriculitis, Cerebral
What is being tested?
Observational sampling of CSF timed around routine clinical repositioning, or not
How many people
55 participants
Where
1 siteSweden
Study dates
5 Oct 2017to 26 Apr 2019
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Neuro Intensive Care patients in University Hospital Setting. This is the only NICU unit in the Stockholm region and covers the full population requiring ICU care with EVDs in the area

Who may be able to join

  • patients treated with EVDs at the NICU at the Karolinska University Hospital in Stockholm Sweden during the inclusion period with with next of kin consent.

Who cannot join

  • patients admitted with bacterial or viral CNS infections

Trial locations and contacts

1 site in 1 country.

Sweden1 site
  • Function Preoperative Medicine and Intensive Care, Karolinska University Hospital

    Stockholm, 17176

Other trials in Sweden

About this study

Official title: External Ventricular Drain Infections in Neurosurgical Patients: Diagnostic and Treatment Implications

External ventricular drains (EVD) are small tubes used in neuro-critical care inserted to measure pressure and treat acute build-up of fluid in the brain by draining the cerebrospinal fluid (CSF) in the ventricles, often following an event of traumatic or spontaneous bleeding. While essential to the care of these patients, EVDs run the risk of introducing bacteria into the brain of the patient, causing an EVD associated infection (EVDI). EVDIs are feared complications that are difficult to identify and predict in an intensive care setting. In order to allow for early identification of these infections, CSF is routinely sampled from the EVDs and its constitution analyzed for signs of infection. However, the constitution of the CSF in neuro-critical care patients are often difficult to assess as it is frequently mixed with blood that often clouds clinical decision making. No fast parameter has been found to yet reliably predict or identify these infections, resulting in excessive treatment with broad-spectrum antibiotics in this patient group.

EVDI diagnostics rely on mainly CSF analyses and cultures (growth of bacteria in the laboratory). Growing bacteria in the lab may take many days and can seldom guide early decision-making for these infections. Thus, EVDI diagnostics mainly rely on the analysis of the CSF constitution. Many diagnostic criteria rely on the relationship between white and red blood cells in the CSF, with red blood cells being introduced in the CSF following the brain bleed , and white blood cells being seen as a response to infection. These criteria assume that the blood is homogeneous in the CSF. However, from computed tomography (CT) imaging of these patients, it is seen that blood can settle in the brain ventricles.

In this study we aim to test the assumption that blood is homogeneously distributed in the CSF by sampling from the CSF in patients. Two samples are serially drawn allocated to a period between where patients are planned for a clinical repositioning, or not. We hypothesise that a heterogeneous distribution of blood in the CSF (as seen on CT imaging) may allow for the CSF constitution to change in serially drawn CSF samples, and that these changes may be exacerbated in repositioned patients as it may disturb the blood that has settled at the bottom of the ventricles as a result of gravity sedimentation. We further believe that these changes may affect clinical decision making and further complicate EVDI diagnostics.

Read the detailed description

Introduction:

External ventricular drains (EVD) are essential tools in neuro-critical care to treat acute hydrocephalus following traumatic or spontaneous cerebral hemorrhage. While essential, EVDs are associated with feared infections (EVDIs) that may result in long term sequelae and affect long term outcome. It is therefore important to promptly identify and treat EVDIs. EVDI diagnostics are based on cerebrospinal fluid (CSF) analyses and CSF bacterial cultures. Causal agents are commonly pathogens colonizing the skin, which makes suspected infection and true infection difficult to distinguish based on the cultured bacteria alone. Additionally, bacterial cultures may take days to finalize and seldom contribute to early decision making or guiding of antibiotic treatment. Diagnostics are thus mainly based on CSF analyses of cells, protein, lactate, and glucose. CSF cellularity, in particular, is frequently confounded in this patient group as a result of intraventricular hemorrhage (IVH), which introduces both erythrocytes and leukocytes into the CSF. To account for IVH, the ratio of erythrocytes and leukocytes (LE ratio) is used and is a central metric in the diagnostics of EVDIs. The LE ratio is based on the assumption that as bacteria is introduced into the CSF, leukocytes will increase in relationship to erythrocytes as a part of the immune response. The LE ratio further assumes that blood is homogeneously distributed in the CSF. However, it is clear from computed tomography (CT) imaging that blood is congregated to the bottom of the ventricles as a result of gravity sedimentation, indicating a heterogeneous sample space. Additionally, leukocytes and erythrocytes exhibit different properties in terms of density which causes a separation during gravity sedimentation. Leukocytes, and granulocytes in particular, may also exhibit upwards floatation due to density changes as they become activated as part of the inflammatory response. Thus, not only is an intraventricular separation of blood and CSF probable, but also a separation of individual cell types. As CSF is sampled from the EVD, a heterogeneous sample space may affect the constitution of sampled CSF depending on the location of the EVD in the ventricles and the location and distribution of intraventricular blood.

Hypothesis:

We hypothesized that blood is heterogeneously distributed in the CSF, and as a result, may introduce CSF parameter variability as the intraventricular distribution of blood and CSF may vary between samples. Furthermore, we believe that routine patient care, such as repositioning of the patient may be enough to cause such a variability.

Study protocol:

Paired CSF samples are collected from patients included in the study, instead of the routine single sample, bi-weekly or during workup for suspected infection. The resulting extra collected CSF from paired samples will amount to approximately 1-2 mL per session. Patients will be allocated to the collection of paired CSF samples around a routine patient repositioning, or a 10 minute wait time between paired CSF samples as identified as the average time between samples when a repositioning was performed during the burn a period. Patients in a lateral side position 2-3 hours prior to CSF sampling will be sampled on either side of a clinical repositioning. Open drains will be closed five minutes prior to the first sample as per clinical routine. 1,5 mL of CSF is drawn and discarded prior to each individual sample.

The following information should be documented for each sample session:

Patient ID:

Study sample nr for this patient:

Date:

Time in a lateral side position prior to sample 1:

Time of sample 1:

Time of repositioning (if repositioned):

Time of sample 2:

GCS:

GCS motor score:

Antibiotic treatment, yes/no:

If suspected/confirmed EVDI, date of diagnosis:

For sample 1 and sample 2:

CSF-Leukocytes:

CSF-Monocytes:

CSF-Granulocytes:

CSF-Erythrocytes:

CSF-Albumin:

CSF: Lactate:

CSF: Glucose:

Additional information is collected for each patient at study inclusion:

Name and social identification number:

Sex:

Main admission diagnosis:

Date of admission:

Date of study inclusion:

Based on the first CT scan after EVD insertion:

Intraventricular hemorrhage score 1-23:

Measured intraventricular blood volume:

Depth of intraventricular sediment in the dorsal horns of the lateral ventricles:

Two dimensional length from the tip of the EVD catheter to blood or sediment:

Patient inclusion:

Over18 years of age in treated in the NICU with inserted EVDs. Patient inclusion was based on written informed consent from nearest of kin.

Statistical analyses:

One-way tests such as the Wilcoxon signed rank test and the Fligner-Killen test of variance will be used to evaluate pair-wise differences and differences between sample groups. Mixed effects regression analyses will be used to evaluate independent predictors of CSF parameter change and to evaluate the correlation between change and demographic variables, such as CT derived variables. Patient ID will be included as a random effect to eliminate inter-individual differences.

Being tested
Observational sampling of CSF timed around routine clinical repositioning, or not
Keywords
External ventricular drain, Infection, cell count
Medical subject headings
Cerebral Ventriculitis, Infections

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Observational sampling of CSF timed around routine clinical repositioning, or notOther

    no true intervention

Study groups in NCT04736407
Study groupRoleWhat they receive
RepositionedAllocated to sampling performed around a standard clinical repositioning (lateral side to side), or a 10 minute wait period between two serially drawn CSF samples, for each biweekly routine CSF infection surveillance sampling.
Receives: Other: Observational sampling of CSF timed around routine clinical repositioning, or not
Non-repositionedAllocated to sampling performed with a 10 minute wait period between two serially drawn CSF samples, for each biweekly routine CSF infection surveillance sampling
Receives: Other: Observational sampling of CSF timed around routine clinical repositioning, or not

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Suspected infection

    Changes in diagnostic group following standard diagnostic criteria

    Measured: 10 minutes

  2. CSF cell count changes between paired samples

    CSF parameter differences and variability between paired samples

    Measured: 10 minutes

Secondary outcomes (1)
  1. Other diagnostic parameters

    CSF lactate, glucose and albumin differences and variability between paired samples

    Measured: 10 minutes

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted3 Feb 2021
  2. Study start5 Oct 2017
  3. Primary completion26 Apr 2019
  4. Study completion26 Apr 2019

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Prospective
Enrolment
55 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04736407
Sponsor's protocol ID
2017-3456
Acronym
EVD-Infect
Status last verified
Jan 2021
First submitted
29 Jan 2021
Last updated
3 Feb 2021
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Badholm M, Blixt J, Glimaker M, Ternhag A, Hedlund J, Nelson DW. Cerebrospinal fluid cell count variability is a major confounding factor in external ventricular drain-associated infection surveillance diagnostics: a prospective observational study. Crit Care. 2021 Aug 11;25(1):291. doi: 10.1186/s13054-021-03715-1.

    PubMed 34380543

Questions about this trial

What is this clinical trial studying?

An observational study of Ventriculitis, Cerebral, run by Karolinska University Hospital at 1 site in Sweden.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 3 Feb 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Sweden. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Suspected infection (time frame: 10 minutes). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04736407, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Feb 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in